Nationwide estimates of patient numbers and prevalence rates of ulcerative colitis and Crohn's disease in Japan in 2023
- PMID: 40892110
- DOI: 10.1007/s00535-025-02295-z
Nationwide estimates of patient numbers and prevalence rates of ulcerative colitis and Crohn's disease in Japan in 2023
Abstract
Background: Almost a decade has passed since the previous nationwide survey on the prevalence of ulcerative colitis (UC) and Crohn's disease (CD) in Japan was conducted in 2015. We conducted a new nationwide hospital-based survey to provide updated estimates of the patient numbers and prevalence rates of UC and CD in Japan in 2023.
Methods: Stratified random sampling was used to select hospital departments (internal medicine, surgery, pediatrics, and pediatric surgery) that routinely treat UC and CD patients. We sent questionnaires to the sampled departments to request sex-specific information on their patient numbers for UC and CD in 2023. Based on the responses, we estimated the annual patient numbers and prevalence rates of UC and CD throughout Japan. The estimates were compared with those from the previous 2015 survey.
Results: The overall survey response rate was 50.8% (1,798/3,538 departments). The estimated patient numbers were approximately 316,900 (95% confidence interval: 223,900-409,900) for UC and 95,700 (61,100-130,400) for CD, both of which represent a 1.4-fold increase over the 8-year period since 2015. The annual prevalence rates per 100,000 population were 254.8 (male: 297.5; female: 214.4) for UC and 77.0 (male: 112.9, female: 43.0) for CD. The male-to-female ratios were 1.31 for UC and 2.49 for CD, and the UC-to-CD ratio was 3.31.
Conclusions: The patient numbers and prevalence rates of UC and CD have continued to steadily increase in Japan, suggesting the need for continued monitoring and further investigation to track the disease burden.
Keywords: Crohn’s Disease; Inflammatory Bowel Disease; Japan; Prevalence; Ulcerative Colitis.
© 2025. The Author(s), under exclusive licence to Japanese Society of Gastroenterology.
Conflict of interest statement
Declarations. Conflict of interest: AT and YM received commissioned research funding from Daiichi Sankyo Company, Limited for the Department of Medical Statistics, Toho University in the past 36 months. AT also holds stock in AstraZeneca PLC. YM also served on the advisory board for Cardiopoint Japan K.K. in the past 36 months. KM received research grants and contracts from Mochida Pharmaceutical Co., Ltd., EA Pharma Co., Ltd., AbbVie GK, and Nippon Kayaku Co., Ltd. in the past 36 months. KM also received consulting fees from Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited, Janssen Pharmaceutical K.K., AbbVie GK, EA Pharma Co., Ltd., Pfizer Japan Inc., Mochida Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Gilead Sciences K.K., Celltrion Healthcare Japan K.K., Eli Lilly Japan K.K., and Bristol-Myers Squibb K.K. in the past 36 months. KM also received payments and honoraria from Mitsubishi Tanabe Pharma Corporation, Takeda Pharmaceutical Company Limited, Janssen Pharmaceutical K.K., AbbVie GK, EA Pharma Co., Ltd., Pfizer Japan Inc., Mochida Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Zeria Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Gilead Sciences K.K., Celltrion Healthcare Japan K.K., Eli Lilly Japan K.K., and Bristol-Myers Squibb K.K. in the past 36 months. TH received research grants from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., AbbVie GK, JIMRO Co., Ltd., Zeria Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., Mochida Pharmaceutical Co., Ltd., Boston Scientific Corporation, and Kissei Pharmaceutical Co., Ltd. in the past 36 months. TH also received consulting fees from Mitsubishi Tanabe Pharma Corporation, EA Pharma Co., Ltd., AbbVie GK, Janssen Pharmaceutical K.K., Pfizer Inc., Eli Lilly, Gilead Sciences, Bristol-Myers Squibb, and Abivax in the past 36 months. TH also received lecture fees from Mitsubishi Tanabe Pharma Corporation, AbbVie GK, EA Pharma Co., Ltd., Kyorin Pharmaceutical Co., Ltd., JIMRO Co., Ltd., Janssen Pharmaceutical K.K., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Pfizer Inc., and Kissei Pharmaceutical Co., Ltd. in the past 36 months.
Similar articles
-
Impact of moderate-to-severe ulcerative colitis and Crohn's disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) survey.Curr Med Res Opin. 2025 Jun;41(6):1017-1030. doi: 10.1080/03007995.2025.2530736. Epub 2025 Jul 17. Curr Med Res Opin. 2025. PMID: 40635574
-
Healthcare resource utilization and production loss in vedolizumab-treated inflammatory bowel disease patients: results from the Swedish prospective multicentre SVEAH study.Therap Adv Gastroenterol. 2025 Jul 17;18:17562848251352023. doi: 10.1177/17562848251352023. eCollection 2025. Therap Adv Gastroenterol. 2025. PMID: 40718705 Free PMC article.
-
Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: A Discrete Choice Experiment Among Patients in Five Non-Western Countries.Adv Ther. 2025 Aug;42(8):3922-3944. doi: 10.1007/s12325-025-03249-w. Epub 2025 Jun 17. Adv Ther. 2025. PMID: 40526254 Free PMC article.
-
Helminth therapy (worms) for induction of remission in inflammatory bowel disease.Cochrane Database Syst Rev. 2014 Jan 20;2014(1):CD009400. doi: 10.1002/14651858.CD009400.pub2. Cochrane Database Syst Rev. 2014. PMID: 24442917 Free PMC article.
-
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2. Cochrane Database Syst Rev. 2021. PMID: 34844288 Free PMC article.
References
-
- Sairenji T, Collins KL, Evans DV. An update on inflammatory bowel disease. Prim Care. 2017;44:673–92. https://doi.org/10.1016/j.pop.2017.07.010 . - DOI - PubMed
-
- Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30. https://doi.org/10.1016/S2468-1253(19)30333-4 . - DOI
-
- Ng SC, Shi HY, Hamidi N, Underwood FE, et al. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2017;390:2769–78. https://doi.org/10.1016/S0140-6736(17)32448-0 . - DOI - PubMed
-
- Hracs L, Windsor JW, Gorospe J, et al. Global evolution of inflammatory bowel disease across epidemiologic stages. Nature. 2025. https://doi.org/10.1038/s41586-025-08940-0 . - DOI - PubMed - PMC
-
- Prideaux L, Kamm MA, De Cruz PP, et al. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012;27:1266–80. https://doi.org/10.1111/j.1440-1746.2012.07150.x . - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources